TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets. The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™. TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026. Initial extended-territ
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-24 2:55 AM EDT | TempraMed Technologies Ltd.
Hemostemix Non Brokered Private Placement
Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and
Biotechnologies, Pharmaceutique, Santé
2026-09-23 4:10 PM EDT | Hemostemix Inc.
Unbuzzd Wellness Appoints Michael "Zappy" Zapolin as CEO to Lead Innovative, Clinically Validated Alcohol Metabolism Accelerant
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM ("unbuzzd") - the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin ("Zappy") as CEO. This marks a pivotal milestone in the Company. His mandate includes finan
2026-09-23 4:00 PM EDT | Unbuzzd Wellness Inc.
HarmonyRx Appoints Daniel Frisbie as Chief Financial Officer
New York, New York--(Newsfile Corp. - September 23, 2026) - HarmonyRx, a transparent, clinically driven pharmacy benefits organization, today announced the appointment of Daniel Frisbie, as Chief Financial Officer. In this role, Frisbie will lead the company's financial strategy, accounting operations, financial planning and reporting while supporting HarmonyRx's continued growth and long-term strategic objectives. Frisbie brings extensive experience in public accounting, financial repo
2026-09-23 9:15 AM EDT | HarmonyRx
Telescope Innovations CTO Prof. Jason Hein to Attend Invitation-Only NSF Programmable Cloud Laboratories Kickoff in Washington, DC
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2026) - Telescope Innovations Corp. (CSE: TELI), (OTCQB: TELIF), (FSE: J4U), ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories, and enabling technologies and services for the global pharmaceutical and high-value chemical industries, announces that Chief Technology Officer Prof. Jason Hein has been requested to participate in the National Science Foundation P
Technologies, Produits chimiques, Pharmaceutique
2026-09-23 8:00 AM EDT | Telescope Innovations Corp.
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania. Robert Bitter
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a m
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-23 3:05 AM EDT | TempraMed Technologies Ltd.
Unbuzzd Wellness Announces Completion of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, the scientifically proven beverage formulated to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, announces that it completed the consolidation of its issued and outstanding common shares on the basis of one post-consolidation common share for every 24 pre-consolidation common shares, effective September
2026-09-22 7:24 PM EDT | Unbuzzd Wellness Inc.
DIMERx Secures Second NIH Award to Advance DMX-201 for Sickle Cell Disease
San Francisco, California--(Newsfile Corp. - September 22, 2026) - DIMERx, Inc., a clinical-stage biopharmaceutical company developing novel dimer-based therapeutics, today announced that it has received a Small Business Innovation Research (SBIR) award from the National Heart, Lung, and Blood Institute (NHLBI) to advance DMX-201 for sickle cell disease (SCD). DMX-201 has the potential to become a first-line therapy for acute chest syndrome (ACS), helping reduce acute respiratory distress, sh
Biotechnologies, Pharmaceutique, Santé
2026-09-22 9:00 AM EDT | DIMERx INC.
NuGen Announces Loan Agreement with Sol-Millennium Medical HK Limited
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce the entering into of a loan agreement (the "Loan Agreement") dated September 18, 2026 with Sol-Millennium Medical HK Limited (the "Lender") in the amount of up to C$1.3 million (the "Loan"). The initial advance under the Loan Agreement will be provided to the Company in the amount of C$500,000 following confirma
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-21 7:42 AM EDT | NuGen Medical Devices Inc.
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance. The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in T
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-18 4:45 PM EDT | TempraMed Technologies Ltd.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' eq
Biotechnologies, Pharmaceutique
2026-09-18 4:45 PM EDT | InMed Pharmaceuticals
Richards Group Inc. Announces September 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended September 30, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on September 29, 2026 and will be payable on October 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whethe
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-09-18 11:50 AM EDT | Richards Group Inc.
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-09-18 7:00 AM EDT | Theralase Technologies Inc.
Unbuzzd Wellness Announces Resignation of Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, the scientifically proven beverage formulated to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, announces that Richard Buzbuzian will resign from his position as Chief Executive Officer of the Company, effective October 1, 2026. The Company thanks Mr. Buzbuzian for his contributions and wishes him
2026-09-17 6:25 PM EDT | Unbuzzd Wellness Inc.
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together wit
2026-09-17 10:41 AM EDT | BetterLife Pharma Inc.
Nextleaf Announces Leadership Transition and Strategic Review; Sam Kassem Appointed Interim CEO
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), an innovation-driven Canadian cannabis processor, announces that Emma Andrews has stepped down as Chief Executive Officer, President and a director of the Company. The Board of Directors has appointed Sam Kassem, the Company's current Chief Financial Officer and a director of the Company, as Interim Chief Executive Officer
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-09-15 7:50 PM EDT | Nextleaf Solutions Ltd.
La Vie Health and Virotek Biosciences Partner to Advance the Next Generation of Precision Health
Ontario and Richmond Hill, Ontario--(Newsfile Corp. - September 15, 2026) - La Vie Health ("La Vie") and Virotek Biosciences ("Virotek") today announced a strategic collaboration to integrate advanced genomic insights into La Vie's broader physician-led preventative, precision and healthspan model. This partnership advances both companies' commitment to precision health, with Virotek adding a clinically contextualized genomic layer to La Vie's comprehensive precision-health prog
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-15 8:30 AM EDT | Virotek Biosciences Inc.
Extendicare Announces September 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - September 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of September 2026, which is payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-15 8:00 AM EDT | Extendicare Inc.
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice ("GLP") toxicology analysis of intravenously administered Ru
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-09-15 7:00 AM EDT | Theralase Technologies Inc.